TEWAMOTO Unveils HydraX Electric Personal Watercraft Concept at the Miami International Boat Show

MIAMI, Feb. 14, 2026 /PRNewswire/ -- TEWAMOTO, a U.S.-registered and globally focused mobility brand, unveiled its HydraX electric personal watercraft design concept at the Miami International Boat Show, showcasing its latest vision for high-performance electric mobility on the water.

"HydraX is more than a design concept — it reflects TEWAMOTO's long-term thinking about the future of water mobility," said Wayne Wang, Founder and Chief Operating Officer of TEWAMOTO. "We believe that meaningful electrification is not simply about changing the power source, but about redefining the balance between performance, freedom, and environmental responsibility. With HydraX, we aim to demonstrate that high-performance water sports can be clean, quiet, and genuinely enjoyable."

As the global marine and water sports industry continues to transition toward electrification and sustainability, TEWAMOTO positions HydraX as a forward-looking exploration of how power, environmental impact, and real-world usability can be integrated into the next generation of personal watercraft.

HydraX and the Future of Electric Personal Watercraft Performance

HydraX is a fully electric personal watercraft concept designed for individual water sports enthusiasts who seek exceptional performance while also valuing sustainability and long-term cost efficiency.

Developed around real-world riding scenarios, HydraX addresses several key limitations of traditional gas-powered personal watercraft, including noise, emissions, restricted water access, and high maintenance costs. Its core highlights include:

• Fully electric propulsion, delivering zero emissions and low noise, enabling access to more regulated and environmentally sensitive waterways.
• A high-output electric powertrain exceeding 240 horsepower, positioning HydraX among the most powerful electric personal watercraft concepts in the industry.
• 5C ultra-fast charging capability, allowing the battery to recharge from 30% to 90% in approximately five minutes, significantly reducing downtime.
• Lower total cost of ownership, minimizing long-term maintenance and energy expenses while enhancing overall riding enjoyment.

Rather than focusing solely on peak performance figures, HydraX emphasizes stable power delivery, usability, and reliability across high-frequency riding scenarios, reflecting TEWAMOTO's user-centered approach to electric mobility design.

Miami: A Global Stage for the Future of Electric Water Mobility

The Miami International Boat Show is one of the world's most influential events for the marine and water sports industry, bringing together leading brands, professionals, and enthusiasts from around the globe. TEWAMOTO's decision to debut HydraX at the show underscores its commitment to engaging the global market in a broader dialogue on the next phase of electric personal watercraft development.

The unveiling of HydraX also marks an important milestone in TEWAMOTO's expansion beyond electric two-wheel mobility, extending its technological capabilities and design philosophy into water-based applications.

About TEWAMOTO

As a U.S.-registered, based, and globally focused international company, TEWAMOTO brings together top talent in design, engineering, and manufacturing from around the world. Our mission is simple yet ambitious: to deliver clean, powerful, and fun mobility experiences for the next generation of riders. We are not just building vehicles — we are building a new way of moving, playing, and living with energy.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

TEWAMOTO Unveils HydraX Electric Personal Watercraft Concept at the Miami International Boat Show

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth

LONDON, March 13, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT, is reinforcing its position as a leading provider of advanced imaging and guided therapy solutions for urologists at the 41^st Annual European Association of Urology (EAU) Congress, currently underway in London (13-16 March 2026).

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now available on the new MyLab™E85 GTS. Esaote will also present  the new MyLab™C30 GTS, extending high image quality performance on a portable system that allow to meet different examination settings.

Throughout the Congress, Esaote (Booth N16) is showcasing a comprehensive portfolio designed to support diagnosis precision and intervention guidance in prostate care, with a strong focus on confidence, efficiency and clinical excellence. PAM Technology is at the core of this innovation, offering automatic analysis of prostate mpMRI volumes and identifying suspicious regions of interest, therefore assisting urologists on enhancing target guidance and decision making.

"PAM Technology is fully integrated into Esaote's UroFusion software," said Marta Daniel, Guided Therapy Product and Clinical Solutions Manager at Esaote. "Our UroFusion package is designed to provide focal guidance during prostate targeted biopsies. Thanks to A.I., urologists have a seamless workflow, with similar duration as a standard biopsy exam, while improving  confidence and accuracy during their biopsy procedures."

During the congress Esaote is also actively participating in TP Biopsy and MRI-US Fusion hands-on sessions, guided by internationally recognised specialists and offering attendees the opportunity to experience the latest advances on UroFusion.

Esaote's presence at EAU 2026 – with the introduction of PAM Technology and the launch of two urology dedicated systems - marks a significant expansion of Esaote's Guided Therapy Solutions (GTS) line and highlights the Company's ongoing commitment to empowering urologists with reliable, intelligent and clinically relevant imaging solutions that provide advanced image quality, intuitive interaction and seamless fusion workflows in prostate care.

Esaote Group is a leader in medical imaging (ultrasound, MRI and diagnostic process management software). At the end of 2025, the Group counts 1,300 employees, half of which are based in Italy. With facilities in Genoa and Florence and its own production and research units in Italy and the Netherlands, Esaote is present in over 100 countries worldwide. www.esaote.com

 

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth

LONDON, March 13, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT, is reinforcing its position as a leading provider of advanced imaging and guided therapy solutions for urologists at the 41^st Annual European Association of Urology (EAU) Congress, currently underway in London (13-16 March 2026).

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now available on the new MyLab™E85 GTS. Esaote will also present  the new MyLab™C30 GTS, extending high image quality performance on a portable system that allow to meet different examination settings.

Throughout the Congress, Esaote (Booth N16) is showcasing a comprehensive portfolio designed to support diagnosis precision and intervention guidance in prostate care, with a strong focus on confidence, efficiency and clinical excellence. PAM Technology is at the core of this innovation, offering automatic analysis of prostate mpMRI volumes and identifying suspicious regions of interest, therefore assisting urologists on enhancing target guidance and decision making.

"PAM Technology is fully integrated into Esaote's UroFusion software," said Marta Daniel, Guided Therapy Product and Clinical Solutions Manager at Esaote. "Our UroFusion package is designed to provide focal guidance during prostate targeted biopsies. Thanks to A.I., urologists have a seamless workflow, with similar duration as a standard biopsy exam, while improving  confidence and accuracy during their biopsy procedures."

During the congress Esaote is also actively participating in TP Biopsy and MRI-US Fusion hands-on sessions, guided by internationally recognised specialists and offering attendees the opportunity to experience the latest advances on UroFusion.

Esaote's presence at EAU 2026 – with the introduction of PAM Technology and the launch of two urology dedicated systems - marks a significant expansion of Esaote's Guided Therapy Solutions (GTS) line and highlights the Company's ongoing commitment to empowering urologists with reliable, intelligent and clinically relevant imaging solutions that provide advanced image quality, intuitive interaction and seamless fusion workflows in prostate care.

Esaote Group is a leader in medical imaging (ultrasound, MRI and diagnostic process management software). At the end of 2025, the Group counts 1,300 employees, half of which are based in Italy. With facilities in Genoa and Florence and its own production and research units in Italy and the Netherlands, Esaote is present in over 100 countries worldwide. www.esaote.com

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Esaote at EAU 2026: Introducing Exclusive PAM Technology to Advance Precision in Urological Imaging